Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.66 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.66 |
| ▸ | NQO2 | P16083 | 8/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198659 | 0.92 | MTNR1A (0.69) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5263983 | 0.89 | MTNR1A (0.54) | MTNR1AMTNR1BNQO2HTR1A | |
| SCHEMBL5223865 | 0.87 | MTNR1A (0.63) | MTNR1AMTNR1BNQO2HTR1A | |
| SCHEMBL5225818 | 0.85 | MTNR1A (0.49) | MTNR1AMTNR1BNQO2HTR1A | |
| SCHEMBL5227718 | 0.85 | HTR1A (0.59) | MTNR1AMTNR1BNQO2HTR1A | |
| SCHEMBL5225086 | 0.85 | MTNR1A (0.57) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL8888092 | 0.81 | MTNR1A (0.83) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL135119 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5263981 | 0.81 | MTNR1A (0.57) | MTNR1AMTNR1BNQO2HTR1A | |
| SCHEMBL8887067 | 0.80 | MTNR1A (0.73) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885MTNR1B 2/4885NQO2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.